TCTR20210822002招募中不适用
Immunogenicity against SARS-CoV-2 variants of concern of ChAdOx1 nCoV-19 vaccine, Sinovac's CoronaVac vaccine, heterologous vaccines and the third boosting vaccine in the elderly and COPD patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 60 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1.Elderly (age >60 years) subjects and spirometry-confirmed COPD patients at any age
- •2.Receiving any 3 national authorized COVID-19 vaccine regimens (CoronaVac/ChAdOx-1, 2-dose ChAdOx-1 vaccine and 2-dose CoronaVac vaccine)
- •3.Boosting with either virus-vectored or mRNA vaccine following standard 2-dose of CoronaVac vaccine
排除标准
- •1.No history of previously diagnosed COVID-19 except positive control group
- •2.No history of COPD exacerbation within previous 3 months
- •3.High-risk of active infection within 14 days before enrollment e.g. close contact with index cases or visiting/ living in outbreak area
- •4.History of receiving other vaccines against SARS-CoV-2
- •5.Participating in other vaccine clinical trial
- •6.History of receiving blood products, blood components, or immunoglobulin within the past 90 days
- •7.History of receiving attenuated live vaccine in the past 28 days
- •8.History of receiving inactivated or subunit vaccines in the past 14 days
- •9.History of allergy to any vaccine component
- •10.Underlying uncontrolled diabetes, uncontrolled cardiovascular disease, uncontrolled pulmonary disease, end-stage renal disease requiring dialysis, cirrhosis, immunocompromised host or receiving immunosuppressive agents
- •11.Unable to make the decision and sign consent by themselves
研究者
相似试验
已完成
不适用
SARS-CoV-2 specific immunity in patients with congenital immune deficienciesNL-OMON50905Academisch Medisch Centrum15
已完成
不适用
Immune response to COVID-19 vaccination in patients with autoimmune disorders on various types of immunosuppressive treatmentsImmune response to COVID-19 (SARS-CoV-2 infection) vaccination in patients on immunosuppressive therapyInfections and InfestationsISRCTN68832164Charles University199
进行中（未招募）
1 期
Study of Recombinant Protein Vaccines with Adjuvant as a Primary Series and as a Booster Dose against COVID-19 in Adults 18 Years of Age and OlderCOVID-19MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-003370-41-ESSanofi Pasteur Inc.5,412
已完成
Unknown
T2B! immunity after SARS-CoV-2<p>SARS-CoV-2, auto-immune diseases,</p>10003816NL-OMON23600ZonMw3,361
招募中
不适用
Immunity against SARS-CoV-2 in immune-suppressed patients: increased risk of insufficient immunological memory or sufficient protection against re-infection? A Target to B! substudyhematologische en andere B-cel gemedieerde aandoeningenimmunityimmunosuppressive medicationSARS-CoV-2 infection1000381610047438NL-OMON55289Academisch Medisch Centrum5,350